Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 16, 2016, Pages 4476-4481

  Kloepper, Jonas ^a   Riedemann, Lars ^a,e,f   Amoozgar, Zohreh ^a   Seano, Giorgio ^a   Susek, Katharina ^a   Yu, Veronica ^a   Dalvie, Nisha ^a   Amelung, Robin L ^a   Datta, Meenal ^a,b   Song, Jonathan W ^a,g   Askoxylakis, Vasileios ^a   Taylor, Jennie W ^a,c,h   Lu Emerson, Christine ^a,c,i   Batista, Ana ^a,j   Kirkpatrick, Nathaniel D ^a,k   Jung, Keehoon ^a   Snuderl, Matija ^a,l   Muzikansky, Alona ^a   Stubenrauch, Kay G ^d   Krieter, Oliver ^d   Wakimoto, Hiroaki ^a   Xu, Lei ^a   Munn, Lance L ^a   Duda, Dan G ^a   Fukumura, Dai ^a   Batchelor, Tracy T ^c   Jain, Rakesh K ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Tufts University   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g Ohio State University   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MAINE MEDICAL CENTER   (United States)

^j Cell Press   (United States)

^k NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^l NEW YORK UNIVERSITY   (United States)

more..

Author keywords

Anti angiogenic therapy; Anti tumor immunity; Macrophage polarization; Microglia reprogramming; Tumor microenvironment

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN 2 ANTIBODY; ANGIOPOIETIN 2 VASCULAR ENDOTHELIAL CELL GROWTH FACTOR BISPECIFIC ANTIBODY; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD45 ANTIGEN; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTIBODY; VASCULOTROPIN; ANG2 PROTEIN, MOUSE; C11ORF2 PROTEIN, HUMAN; CANCER ANTIBODY; PANCREATIC RIBONUCLEASE; TUMOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CAPILLARY DENSITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MACROPHAGE; MALE; MICROGLIA; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; MACROPHAGES; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; RIBONUCLEASE, PANCREATIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964402874     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1525360113     Document Type: Article

References (67)

1. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996.
2. Lu-Emerson C, et al. (2015) Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33(10):1197-1213.
3. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131-1138.
4. Kreisl TN, et al. (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745.
5. Friedman HS, et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740.
6. Gilbert MR, et al. (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699-708.
7. Chinot OL, et al. (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709-722.
8. Batchelor TT, et al. (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212-3218.
9. ∗phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: The EORTC 26101 trial. Neuro-oncol 17(suppl 5):v1-v1.
10. Chae S-S, et al. (2010) Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16(14):3618-3627.
11. Maisonpierre PC, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55-60.
12. Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res 72(8):1909-1914.
13. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10(3):165-177.
14. Daly C, et al. (2013) Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73(1):108-118.
15. Venneri MA, et al. (2007) Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109(12):5276-5285.
16. Gabrusiewicz K, et al. (2014) Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 5(8):2208-2220.
17. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE (2008) Astrocytic regulation of human monocytic/microglial activation. J Immunol 181(8):5425-5432.
18. Li W, Graeber MB (2012) The molecular profile of microglia under the influence of glioma. Neuro-oncol 14(8):958-978.
19. Coffelt SB, et al. (2011) Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 186(7):4183-4190.
20. De Palma M, et al. (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211-226.
21. Pucci F, etal. (2009) A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114(4):901-914.
22. Coffelt SB, et al. (2010) Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 70(13):5270-5280.
23. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 122(3):787-795.
24. Noy R, Pollard JW (2014) Tumor-associated macrophages: From mechanisms to therapy. Immunity 41(1):49-61.
25. Mantovani A, Allavena P (2015) The interaction of anticancer therapies with tumorassociated macrophages. J Exp Med 212(4):435-445.
26. Lu-Emerson C, et al. (2013) Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-oncol 15(8):1079-1087.
27. Brown JL, et al. (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9(1):145-156.
28. Kienast Y, et al. (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19(24):6730-6740.
29. Rigamonti N, etal. (2014) Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Reports 8(3):696-706.
30. Hashizume H, et al. (2010) Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70(6):2213-2223.
31. Hidalgo M, et al. (2014) Results from the first-in-human (FIH) phase I study of RO5520985(RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors. ASCO Meeting Abstracts 32(15-suppl):2525.
32. Murat A, et al. (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26(18):3015-3024.
33. Lambiv WL, et al. (2011) The Wnt inhibitory factor 1(WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-oncol 13(7):736-747.
34. Barrett T, et al. (2013) NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res 41 (Database issue):D991-D995.
35. Wurdinger T, et al. (2008) A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 5(2):171-173.
36. Tannous BA (2009) Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 4(4):582-591.
37. Kodack DP, et al. (2012) Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci USA 109(45):E3119-E3127.
38. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417-427.
39. Jain RK (2014) Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26(5):605-622.
40. Keskin D, et al. (2015) Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Reports 10(7):1066-1081.
41. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307.
42. Dvorak HF (2015) Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. Cancer J 21(4):237-243.
43. Peterson TE, et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA 113:4470-4475.
44. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133(1):95-109.
45. Tolaney SM, et al. (2015) Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci USA 112(46):14325-14330.
46. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103(2):159-165.
47. Emblem KE, et al. (2013) Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19(9):1178-1183.
48. Emblem KE, et al. (2014) Vessel caliber-a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol 11(10):566-584.
49. Grenga I, Kwilas AR, Donahue RN, Farsaci B, Hodge JW (2015) Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. J Immunother Cancer 3:52.
50. Gajewski TF, Schreiber H, Fu Y-X (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014-1022.
51. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423-1437.
52. Wu J, Waxman DJ (2015) Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 (+) T-cell responses and immune memory. OncoImmunology 4(4):e1005521.
53. Wagner S, et al. (1999) Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 82(1):12-16.
54. Zhai H, Heppner FL, Tsirka SE (2011) Microglia/macrophages promote glioma progression. Glia 59(3):472-485.
55. Meisen WH, et al. (2015) The impact of macrophage- and microglia-secreted TNFα on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clin Cancer Res 21(14):3274-3285.
56. Lorke DE, Ip CW, Schumacher U (2008) Increased number of microglia in the brain of severe combined immunodeficient (SCID) mice. Histochem Cell Biol 130(4):693-697.
57. Ott PA, Hodi FS, Buchbinder EI (2015) Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 5:202.
58. Wakimoto H, et al. (2009) Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69(8):3472-3481.
59. Yuan F, et al. (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54(17):4564-4568.
60. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285(21):1182-1186.
61. Liang W-C, et al. (2006) Cross-species vascular endothelial growth factor (VEGF) - blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281(2):951-961.
62. Thomas M, et al. (2013) A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PLoS One 8(2):e54923.
63. Schaefer W, et al. (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108(27):11187-11192.
64. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4(11):2411-2423.
65. Song JW, Bazou D, Munn LL (2012) Anastomosis of endothelial sprouts forms new vessels in a tissue analogue of angiogenesis. Integr Biol (Camb) 4(8):857-862.
66. Duffy DC, McDonald JC, Schueller OJ, Whitesides GM (1998) Rapid prototyping of Microfluidic Systems in Poly (dimethylsiloxane). Anal Chem 70(23):4974-4984.
67. Song JW, Munn LL (2011) Fluid forces control endothelial sprouting. Proc Natl Acad Sci USA 108(37):15342-15347.